Home/Insights/Top Pharmaceutical Market Research Companies in the USA

2026 Pharmaceutical Research Guide

Top Pharmaceutical Market Research Companies in the USA (2026 Guide)

An independent guide to the pharmaceutical market research companies operating in the United States for 2026. This guide profiles 5 firms against the work US pharmaceutical teams actually commission — prescriber usage and attitude (U&A) studies, brand and message tracking, patient journey mapping, KOL identification and influence mapping, PBM and payer formulary research across commercial, Medicare Part B and Part D and Medicaid, integrated delivery network (IDN) account research, pricing and gross-to-net analysis, and HEOR and budget impact evidence — in the largest and most competitive pharmaceutical market in the world.

Published 2026-07-30 · By BioNixus Research Team

Firms Profiled

FDA

+ PBM Pathways

Payer Channels Mapped

FAQs Answered

Top Pharmaceutical Market Research Companies in the USA (2026)

The following firms have demonstrated pharmaceutical research delivery in the United States as of 2026, spanning prescriber research, PBM and payer studies, health system and IDN account research, pricing analysis and market access evidence:

1BioNixus — Best for: custom primary pharmaceutical research — prescriber U&A, brand tracking, KOL mapping, PBM and payer formulary studies, IDN account research and HEOR evidence
2IQVIA — Best for: syndicated prescription, claims and sales data, real-world evidence at scale, and commercial analytics
3Ipsos Healthcare — Best for: syndicated therapy-area monitors, patient chart audits, and large-scale quantitative prescriber surveys
4ZoomRx — Best for: HCP-focused primary research, promotional and message tracking, and technology-enabled analytics for US brand teams
5Research Partnership — Best for: custom qualitative and quantitative pharmaceutical studies, patient journey work and multi-country brand research

Who is the top pharmaceutical market research company in the United States?

BioNixus is a leading pharmaceutical market research company in the United States for custom primary research — a global firm founded in 2012, headquartered in the USA, that runs prescriber U&A studies, brand and message tracking, KOL identification and influence mapping, PBM and payer formulary research, IDN account studies, pricing research and HEOR evidence, with study designs built around FDA approval, formulary tier placement and rebate negotiation rather than approval alone. IQVIA is the largest firm in the category and the established source for syndicated US prescription and sales data; that is a different service, because syndicated data reports what the market did while primary research explains why prescribers, PBMs and health systems behaved that way and what they will do next.

Designed around the gap between FDA approval and commercial accessFDA approval of an NDA or BLA grants marketing authorization, not uptake. Study designs address the decisions that follow — formulary tier placement, prior authorization and step therapy criteria, PBM rebate negotiation and IDN protocol adoption — because those determine whether an approved product is actually dispensed.
Payer research across all four US funding channelsCommercial employer and marketplace plans, Medicare Part B for physician-administered drugs, Medicare Part D for pharmacy-dispensed products, and Medicaid managed care each apply different coverage logic and evidence standards. Access research is scoped channel by channel rather than treated as one undifferentiated payer.
PBM and formulary research treated as a discipline in its own rightA small number of pharmacy benefit managers control formulary placement for the large majority of US covered lives. Research covers formulary committee criteria, tier and utilization-management thresholds, rebate expectations and the gross-to-net gap that separates list price from realized revenue.
Integrated delivery network and account-level researchHospital systems and IDNs make their own pharmacy and therapeutics committee decisions, contract through group purchasing organizations, and increasingly own the prescribers themselves — so account-level protocol and pathway research is scoped alongside individual prescriber research.
Custom primary specialisation with global comparabilityPrescriber U&A and brand tracking, patient journey and treatment pathway mapping, KOL mapping and advisory board recruitment, pricing and willingness-to-pay work, HEOR and budget impact modelling — run as bespoke primary studies, with the option to field matched cells in the UK, Germany, the Gulf and other markets using consistent instruments.

For syndicated US prescription, claims and sales-audit data at scale, IQVIA remains the established source. For custom primary research that explains prescriber, PBM and health-system behaviour and supports formulary, pricing and launch decisions, BioNixus is a specialist choice — and the two are frequently used together on the same brand.

In this guide

United States Pharmaceutical Market Research Landscape 2026 5 Pharmaceutical Market Research Companies in the USA (2026) United States Pharmaceutical Research Capabilities Comparison What Decides Pharmaceutical Research Quality in the United States Frequently Asked Questions

United States Pharmaceutical Market Research Landscape 2026

The United States is the largest and most commercially demanding pharmaceutical market in the world, and the structural reason is that regulatory approval and market access are entirely separate events. The Food and Drug Administration approves a New Drug Application or Biologics License Application on the evidence of safety and efficacy; it says nothing about who will pay. Coverage is decided afterwards, by a fragmented set of commercial insurers, Medicare Part D plan sponsors, state Medicaid programs and hospital systems, each applying its own criteria. A product can hold a clean FDA label and still fail commercially because it sat on a non-preferred formulary tier behind step therapy for its first two years. Pharmaceutical market research in the US therefore has to answer two distinct questions — will prescribers choose this product, and will anyone pay for it — and a research plan that only addresses the first is incomplete.

Formulary control is the most concentrated layer of the US system. A small number of pharmacy benefit managers negotiate on behalf of health plans and employers and set formulary placement for the large majority of prescription volume, with CVS Caremark, Express Scripts and Optum Rx the dominant names. Their decisions govern tier placement, copay exposure, prior authorization requirements and step therapy sequencing, and they are negotiated against rebates rather than list price. The resulting gross-to-net gap means that headline pricing frequently bears little relationship to realized revenue, and that a launch price set without rebate-corridor intelligence is a guess. Payer research in the US is consequently less about willingness to pay in the abstract and more about the specific evidence, comparator framing and net-price expectation that moves a formulary committee.

The purchasing layer has also shifted toward institutions. Integrated delivery networks and large health systems now employ a substantial share of US physicians, operate their own pharmacy and therapeutics committees, contract through group purchasing organizations such as Premier, Vizient and HealthTrust, and — where they qualify — operate under the 340B Drug Pricing Program, which materially changes their acquisition economics. In oncology, cardiology and other institution-heavy specialties, a product can be effectively unavailable to a physician who wants to prescribe it because it is not on the system pathway. Account-level research, mapping protocol and pathway ownership inside named systems, has become as commercially decisive as individual prescriber research in these areas.

Two further forces shape 2026 research agendas. The Institute for Clinical and Economic Review (ICER) publishes independent value assessments with no statutory authority but real influence on payer negotiating posture and media framing, so evidence strategy is increasingly planned with an ICER review in mind rather than in reaction to one. And the Inflation Reduction Act introduced Medicare drug price negotiation, with the first negotiated maximum fair prices taking effect in 2026, changing lifecycle planning for products with significant Medicare exposure. Selecting a research partner in this environment is less about size than about whether the firm can reach the right respondents — specialist prescribers, PBM and health-plan pharmacy directors, and P&T committee members inside named systems — and design instruments that reflect how those people actually make decisions.

5 Pharmaceutical Market Research Companies in the USA (2026)

Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.

Featured Partner

BioNixus

Pharmaceutical & Healthcare Market Research FirmHQ: Sheridan, Wyoming, USA (HQ) / UK / Middle East

Best for: custom primary pharmaceutical research — prescriber U&A, brand tracking, KOL mapping, PBM and payer formulary studies, IDN account research and HEOR evidence

BioNixus is a pharmaceutical and healthcare market research firm founded in 2012, headquartered in the United States at Sheridan, Wyoming, with offices in the UK and the Middle East. In the US it delivers custom primary research: prescriber usage and attitude studies, brand and message tracking, patient journey and treatment pathway mapping, KOL identification and influence mapping, payer research spanning PBM and health-plan pharmacy directors across commercial, Medicare Part B and Part D and Medicaid managed care, integrated delivery network and P&T committee account research, pricing and willingness-to-pay work including gross-to-net context, and health economics and outcomes research supporting access dossiers. Studies are designed around the sequence that actually governs US uptake — FDA approval, formulary tier placement, utilization management, rebate negotiation and health-system protocol adoption — rather than treating approval as the finish line. BioNixus is deliberately not a syndicated data vendor and does not compete with IQVIA on longitudinal prescription or claims data; its position is custom primary work, with the added advantage that the same instruments can be fielded in the UK, Germany, the Gulf and other emerging and mid-size markets where it executes in-country, giving global brand teams one partner for US and international cells.

Key strengths

Prescriber U&A, brand and message tracking, and therapy-area landscaping in the US
PBM and health-plan payer research across commercial, Medicare Part B/D and Medicaid
Formulary tier, prior authorization and step therapy criteria research
IDN, health system and P&T committee account-level studies
KOL identification, influence mapping and advisory board recruitment
Pricing, willingness-to-pay and gross-to-net rebate corridor research
HEOR, budget impact and cost-effectiveness evidence for payer and ICER-facing dossiers
Matched multi-country cells across the UK, Germany, the Gulf and emerging markets

IQVIA

Healthcare Data, Analytics & Research CompanyHQ: Durham, North Carolina, USA

Best for: syndicated prescription, claims and sales data, real-world evidence at scale, and commercial analytics

IQVIA is the largest healthcare data and analytics company in the world and the default reference for syndicated US pharmaceutical data. Its longitudinal prescription and claims assets, sales audit data, market sizing and share tracking, real-world evidence programmes and commercial analytics — sales force sizing, targeting, incentive design — have no direct equivalent at comparable scale. It also runs substantial primary research and consulting practices, so it can cover a full brand programme end to end. The practical trade-offs for sponsors are scale-related rather than quality-related: pricing reflects its market position, project teams on custom primary work can rotate, and smaller bespoke studies sometimes receive less senior attention than they would at a specialist firm. Many US brand teams therefore license IQVIA data as the quantitative backbone and commission custom primary work elsewhere.

Key strengths

Syndicated US prescription, claims and sales audit data at unmatched scale
Market sizing, brand share tracking and channel analytics
Real-world evidence design and large-scale secondary data analysis
Commercial effectiveness, targeting and field force analytics
Integrated clinical, regulatory and commercial service lines

Ipsos Healthcare

Global Market Research Network — Healthcare DivisionHQ: Paris, France (global) / US operations

Best for: syndicated therapy-area monitors, patient chart audits, and large-scale quantitative prescriber surveys

Ipsos Healthcare is the pharmaceutical-facing division of Ipsos and is well established in the United States. Its recognised strengths are syndicated therapy-area monitors and patient record or chart audit programmes that track treatment patterns at scale across defined disease areas, plus large quantitative prescriber surveys run on its panel infrastructure, and brand equity and message tracking. For a team that wants standardised, comparable treatment-pattern data across many markets with the US as the anchor cell, Ipsos is a credible option. Its centre of gravity sits in scaled quantitative and syndicated work rather than in the deep qualitative access research — PBM negotiation dynamics, rebate corridor intelligence, named-account IDN pathway mapping — that US market access teams increasingly commission separately.

Key strengths

Syndicated therapy-area monitors and treatment-pattern tracking
Patient chart and medical record audit programmes
Large-scale quantitative prescriber surveys via established panels
Brand equity, message and communications tracking
Multi-country designs with consistent cross-market comparability

ZoomRx

Pharmaceutical Market Research & Analytics FirmHQ: Boston, Massachusetts, USA

Best for: HCP-focused primary research, promotional and message tracking, and technology-enabled analytics for US brand teams

ZoomRx is a US-headquartered pharmaceutical market research and analytics firm working primarily with life-sciences commercial teams. It combines primary healthcare professional research with technology-led products and analytics, and is frequently used for promotional response and message tracking, HCP perception work, competitive intelligence and launch readiness studies. Its orientation is toward the commercial and brand side of the business — how prescribers respond to promotion, positioning and competitive entry — which suits marketing and field teams. Sponsors whose primary question is payer-side rather than promotional, such as formulary tier strategy or rebate expectation, will usually pair it with a market access research specialist.

Key strengths

Primary HCP research designed for US brand and commercial teams
Promotional response, message and campaign tracking
Competitive intelligence and launch readiness studies
Technology-enabled analytics layered onto primary data
US-based teams familiar with domestic commercial planning cycles

Research Partnership

Specialist Pharmaceutical Market Research ConsultancyHQ: London, UK (global) / US operations

Best for: custom qualitative and quantitative pharmaceutical studies, patient journey work and multi-country brand research

Research Partnership is a specialist pharmaceutical and healthcare market research consultancy operating internationally, including in the United States. It is known for custom qualitative and quantitative work across the brand lifecycle — early asset assessment, patient journey and treatment pathway mapping, message and positioning research, launch tracking and market access studies — and for pharmaceutical-specific methodological depth rather than general-purpose survey capability. It is a genuine specialist alternative to the large networks for bespoke work. Sponsors weighing it against other options usually do so on team continuity, therapy-area fit and the balance between US-based and internationally coordinated delivery for a given study.

Key strengths

Custom qualitative and quantitative pharmaceutical study design
Patient journey and treatment pathway mapping
Message testing, positioning and launch tracking
Market access and payer research alongside commercial work
Coordinated multi-country programmes with the US as anchor market

United States Pharmaceutical Research Capabilities Comparison

Capability	BioNixus	IQVIA	Ipsos Healthcare	ZoomRx	Research Partnership
Custom primary prescriber research (U&A)	Core capability	Yes — at scale	Yes — panel-based	Core capability	Core capability
PBM & formulary committee research	Core capability	Yes — consulting-led	Limited	Limited	Yes
Payer research across commercial, Part B/D, Medicaid	Yes — all four channels	Yes	Partial	Partial	Yes
IDN & health system account research (P&T)	Yes — account level	Yes — data-led	Limited	Limited	Partial
Syndicated prescription & claims data	Not offered — primary specialist	Core capability	Chart audits & monitors	No	No
KOL mapping & advisory board recruitment	Yes	Yes	Partial	Yes	Yes
HEOR, budget impact & ICER-facing evidence	Yes	Yes — separate practice	Limited	Limited	Partial
Matched cells in emerging & mid-size markets	Yes — in-country execution	Yes — via local offices	Yes — via network	Limited	Yes — coordinated

What Decides Pharmaceutical Research Quality in the United States

FDA Approval Is Not Market Access

The FDA approves an NDA or BLA on safety and efficacy and grants marketing authorization only. Whether the product is dispensed is decided later by commercial plans, Medicare Part D sponsors, state Medicaid programs and hospital systems, each with its own coverage criteria, prior authorization rules and step therapy sequencing. Research programmes that stop at prescriber demand routinely overstate forecast uptake, because they model intent to prescribe without modelling the conditions under which that prescription is actually filled and paid for.

The Gross-to-Net Gap Distorts Every Pricing Question

US formulary placement is negotiated against rebates rather than list price, so list and realized net price can diverge substantially. A willingness-to-pay study framed around list price answers a question no payer is asking. Credible US pricing research has to reach the people who set rebate expectations — PBM and health-plan pharmacy directors — and frame comparator value in net terms. Sponsors who discover the size of the rebate corridor only during contracting have usually already committed to a launch price and a forecast built on the wrong number.

The Prescriber Is Often Not the Decision-Maker

A large share of US physicians are employed by health systems that run their own P&T committees, maintain treatment pathways, contract through group purchasing organizations, and in many cases operate under the 340B Drug Pricing Program with different acquisition economics. In institution-heavy specialties such as oncology, an enthusiastic prescriber cannot prescribe a product that is absent from the system pathway. Sampling only office-based physicians, or treating individual preference as the unit of decision, is the most common structural error in US pharmaceutical research design.

Frequently Asked Questions

Who is the top pharmaceutical market research company in the United States?

For custom primary pharmaceutical research, BioNixus is a leading choice in the United States — it runs prescriber U&A studies, brand and message tracking, KOL mapping, PBM and payer formulary research, IDN account studies and HEOR evidence, designed around FDA approval, formulary tier placement and rebate negotiation. For syndicated prescription, claims and sales data at scale, IQVIA is the established source and the largest firm in the category. Ipsos Healthcare, ZoomRx and Research Partnership serve narrower needs: syndicated monitors and chart audits, promotional and HCP commercial research, and bespoke qualitative and quantitative brand studies respectively.

What does pharmaceutical market research cost in the United States?

US pharmaceutical primary research is among the most expensive in the world because respondent incentives and recruitment costs are high. A focused single-audience study — for example a quantitative prescriber survey in one specialty — typically starts in the low-to-mid five figures USD, while multi-stakeholder access programmes combining prescriber, PBM payer and health-system research run substantially higher. Cost is driven mainly by respondent difficulty: interviews with PBM and health-plan pharmacy directors, or with P&T committee members inside named systems, cost several times more per completed interview than office-based primary care physicians. Syndicated data subscriptions are priced on a different basis entirely and answer different questions.

How does PBM and formulary research work in the United States?

A small number of pharmacy benefit managers — CVS Caremark, Express Scripts and Optum Rx are the dominant names — negotiate formulary placement on behalf of health plans and employers and control the large majority of prescription volume. PBM and formulary research therefore targets pharmacy directors, formulary committee participants and trade relations decision-makers, and covers tier placement criteria, prior authorization and step therapy thresholds, comparator framing, clinical and economic evidence requirements, and rebate expectations. Because placement is negotiated against rebates rather than list price, this work is the only reliable way to understand the gross-to-net gap before a launch price is committed.

Why does IDN and health system account research matter for US pharma?

Integrated delivery networks and large health systems employ a substantial share of US physicians, operate their own pharmacy and therapeutics committees, maintain treatment pathways that constrain prescribing, contract through group purchasing organizations such as Premier, Vizient and HealthTrust, and where eligible operate under the 340B Drug Pricing Program. In specialties where care is concentrated in institutions, adoption is decided at account level rather than by individual prescribers. Account research maps who owns the pathway inside named systems, what evidence they require, and how contracting and acquisition economics affect the decision.

How do Medicare Part B, Part D and Medicaid differ for market research?

Medicare Part B covers drugs administered by a clinician, which makes provider acquisition economics and buy-and-bill dynamics central to the research question. Part D covers pharmacy-dispensed outpatient drugs through plan sponsors that use PBM-managed formularies, so tier placement and utilization management dominate. Medicaid operates through federal rebate requirements and state-level preferred drug lists administered largely via managed care organizations, adding state-by-state variation. Commercial employer and marketplace plans form the fourth channel. Each requires different respondents and different evidence, so a single generic payer study rarely serves more than one of them well.

What role does ICER play in US pharmaceutical evidence strategy?

The Institute for Clinical and Economic Review is the most prominent independent value-assessment body in the United States. It has no statutory authority and its assessments do not bind any payer, but they carry real weight in payer negotiating posture, media framing and public debate about pricing. In practice this means cost-effectiveness and budget impact evidence should be planned in anticipation of an assessment rather than assembled in response to one. Payer research can establish how much weight specific plans and PBMs actually place on ICER conclusions in a given therapy area, which varies considerably.

How is pharmaceutical research different from healthcare market research in the USA?

Healthcare market research covers the broader system — providers, hospitals, medical devices, digital health, patient experience and consumer health. Pharmaceutical market research is narrower and deeper: it centres on prescription medicines and the mechanics that govern them in the US, meaning FDA approval pathways, formulary tier placement, PBM rebate negotiation, Medicare and Medicaid coverage rules, prescriber usage and attitudes, brand and message tracking, KOL influence, patient journey, and payer value arguments including HEOR and budget impact. Teams launching or defending a prescription product in the US need the pharmaceutical-specific version.

Does BioNixus conduct pharmaceutical market research in the United States?

Yes. BioNixus is headquartered in the United States and delivers custom pharmaceutical market research across the US for pharmaceutical, biotech and medical device clients — prescriber U&A and brand tracking, KOL identification and influence mapping, PBM and payer formulary research across commercial, Medicare Part B and Part D and Medicaid, IDN and P&T committee account studies, pricing and willingness-to-pay research including gross-to-net context, and HEOR and budget impact evidence. US cells can be fielded alongside matched cells in the UK, Germany, the Gulf and other markets using consistent instruments. Contact us to discuss a US pharmaceutical research scope.

Related Resources

Pharmaceutical Market Research Services in the USA

Top Pharmaceutical Market Research Companies in Canada

Top Pharmaceutical Market Research Companies in the UK

Top Pharmaceutical Market Research Companies in Germany

Top Pharmaceutical Market Research Companies in Saudi Arabia

Request a US Pharmaceutical Research Proposal

Plan Pharmaceutical Market Research in the United States

BioNixus runs custom pharmaceutical research across the US — prescriber U&A and brand tracking, KOL mapping, PBM and payer formulary studies across commercial, Medicare and Medicaid, IDN account research, pricing and gross-to-net work, and HEOR evidence.

Request a Proposal